#  Bo Xia, Ph.D. 

 



   ![Bo Xia](/sites/g/files/omnuum11886/files/styles/hwp_1_1__360x360_scale/public/boxia/files/img_0054-2_0.jpg?itok=945E0Q0j) 

 

**Dr. Bo Xia is a faculty member / Assistant Professor at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute! Before that, he was a** [**Junior Fellow of the Society of Fellows at Harvard University**](https://socfell.fas.harvard.edu/about)**, and** [**Gene Regulation Observatory (GRO) Fellow**](https://www.broadinstitute.org/bios/bo-xia) **and a Principal Investigator at the** [**Broad Institute of MIT and Harvard**](https://www.broadinstitute.org/bios/bo-xia) **from 2022 to 2025. Dr. Xia and his laboratory at Broad and MGH are building biologically grounded technologies to decode genome regulation & engineer cell fates.**

**Dr. Xia develops and applies state-of-the-art genomics technologies – both experimental and computational – to accelerate discoveries in genome sciences. Xia’s career started as an independent research associate in Dr. Chengqi Yi’s lab at Peking University, leading the development of chemical technologies for epigenomic analyses (**[**Xia et al, 2015**](https://www.nature.com/articles/nmeth.3569)**;** [**Zhu et al, 2017**](https://www.sciencedirect.com/science/article/pii/S193459091730070X?via%3Dihub)**). Xia conducted his Ph.D. research at NYU School of Medicine, co-mentored by Drs. Itai Yanai and Jef D. Boeke. Xia pioneered a few innovative studies on genome regulation and its impact on human development and evolution, including revealing the genetic basis of tail-loss evolution in humans and apes (**[**Xia et al, 2024**](https://www.nature.com/articles/s41586-024-07095-8)**); proposing the transcriptional scanning model for modulating genome evolution (**[**Xia et al, 2020**](https://www.sciencedirect.com/science/article/pii/S0092867419313777)**); proposing the hypothesis of periodic table of cell types (**[**Xia and Yanai, 2019**](https://journals.biologists.com/dev/article/146/12/dev169854/19451/A-periodic-table-of-cell-types)**); and most recently, developing multi-modal machine learning-enabled in silico screen approaches for investigating genome regulation and cell fate determination (**[**Tan et al, 2023**](https://www.nature.com/articles/s41587-022-01612-8)**).**

**Dr. Xia is a recipient of multiple prestigious awards, including the** [**2020 Regeneron Prize for Creative Innovation**](https://www.prnewswire.com/news-releases/regeneron-announces-the-2020-winners-of-the-regeneron-prize-for-creative-innovation-301080675.html)**, the** [**Harold M. Weintraub Graduate Student Award (2022)**](https://www.fredhutch.org/en/news/releases/2022/03/2022-harold-m-weintraub-graduate-student-award.html)**,** [**NIH Director's Early Independent Award (2022)**](https://commonfund.nih.gov/earlyindependence/awardrecipients)**, and the 2024 MIT Technology Review Innovators Under 35 (Pioneers). Dr. Xia started his independent laboratory in the Gene Regulation Observatory at the Broad Institute in September 2022. The Xia laboratory develops high-throughput approaches to discover functional DNA elements and novel genome regulators. Their long-term goal is to understand the principles and mechanisms of genome regulation, how they evolve across the tree of life, and how they go awry in diseases.**

**Read more:** [**Xia Laboratory**](https://www.boxialab.org/home)